Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Yokohama
Clinical trial register · Japan

Clinical Trials in Yokohama, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC32 Pfizer27 Novartis Pharmaceuticals27 Bristol-Myers Squibb17 Amgen14
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Yokohama

275 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Sapporo, Yokohama, Suita, Bunkyo-ku, Fukuoka, Maebashi, Okayama
2027-02-03
Not yet open
National Cancer Center, Japan
Phase 2
35
Yokohama, Chuo-ku
2027-02-01
Not yet open
Bayer
Phase 2
8
Nagoya, Yokohama, Toyonaka, Bunkyo-ku, Kyoto
2027-01-25
Not yet open
Bristol-Myers Squibb
Phase 2
80
Kitakyushu, Yokohama, Ōsaka-sayama
2026-11-30
Recruiting
Novartis Pharmaceuticals
Phase 2
120
Yokohama, Suita, Hachiōji, Fukushima
2026-10-30
Not yet open
Risankizumab for Refractory Perianal Fistulizing Crohn's Disease
NCT07872449Crohn Disease, Perianal Fistula, Perianal Fistula Due to Crohn's Disease, Perianal Crohn's Disease
DrugRisankizumab
Yuki Horio
Phase 4
25
Nishinomiya, Shinjuku-Ku, Yokohama
2026-10-01
Not yet open
Pfizer
Phase 3
197
Fukuoka, Kasuya-gun, Sapporo, Amagasaki, Mito, Naka, Yokohama, Minoh
2026-09-28
Recruiting
Novartis Pharmaceuticals
Phase 3
382
Yokohama, Kamimashi-gun
2026-09-21
Recruiting
Daiichi Sankyo
Phase 1/2
220
Kashiwa, Isehara, Yokohama, Hirakata, Chuo-ku, Koto-ku, Shinagawa-ku, Fukuoka
2026-09-17
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 1/2
50
Chiba, Kashiwa, Fukuoka, Hiroshima, Sapporo, Kanazawa, Yokohama, Kyoto
2026-09-15
Recruiting
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC
NCT07733180Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma
DrugsLeucovorin·Adrucil·Tislelizumab·Oxaliplatin
BeOne Medicines
Phase 2
30
Yokohama, ChuoKu, Osaka
2026-09-14
Recruiting
Bristol-Myers Squibb
Phase 3
850
Nagoya, Toon-Shi, Kurume-Shi, Yokohama, Sendai, Okayama, Hirakata-Shi, Osakasayama-Shi
2026-09-08
Recruiting
AstraZeneca
Phase 3
1,072
Kanazawa, Maebashi, Nagoya, Sapporo, Yokohama
2026-08-31
Recruiting
Pfizer
Phase 3
1,375
Nagoya, Kagoshima, Yokohama, Sakai, Saitama, Chuo-ku, Tachikawa, Toshima-ku
2026-08-24
Recruiting
Novartis Pharmaceuticals
Phase 3
180
Yokohama, Sakai, Tachikawa
2026-08-24
Recruiting
AbbVie
Phase 2
168
Yokohama, Osaka, Chuo-Ku
2026-08-17
Recruiting
National Cancer Center, Japan
Phase 2
29
Saitama, Tokyo, Yokohama
2026-08-13
Recruiting
VectivBio AG
Phase 3
124
Yokohama, Saga, Kagawa
2026-08
Recruiting
Amgen
Phase 3
3,200
Yokohama, Chiyoda-ku, Chuo-ku, Hachioji-shi, Minato-ku, Shinjuku-ku, Suginami-ku
2026-07-23
Recruiting
National Cancer Center, Japan
Phase 2
136
Chiba, Fukuoka, Gifu, Maebashi, Hiroshima, Kawasaki, Yokohama, Ina
2026-07-15
Recruiting
Ipsen
Phase 3
350
Chiba, Hiroshima, Itabashi-ku, Yokohama, Ōmura, Kashihara, Niigata, Suita
2026-05-14
Recruiting
Novartis Pharmaceuticals
Observational
10
Kobe, Ushiku, Kanoya, Yokohama, Osaka
2026-05-13
Recruiting
Genmab
Phase 2
160
Kashiwa, Yokohama, Suita, Kōtoku
2026-05-11
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Nagoya, Fukuoka, Yokohama, Sakai-shi, Kitaadachi-gun, Chūōku, Kōtoku, Osaka
2026-05-06
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
DrugsAsciminib single agent·ABL001
Novartis Pharmaceuticals
Phase 2
50
Yokohama, Fukuoka, Saitama
2026-04-28
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
356
Fukuoka, Hiroshima, Sapporo, Yokohama, Tokyo, Natori-shi, Niigata, Hirakata
2026-04-28
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
60
Nagoya, Yokohama, Chūō
2026-03-27
Active, closed
Intuitive Surgical
Observational
625
Ichinomiya, Toyoake, Yokohama, Kyoto, Tsu, Ageo, Tokyo
2026-03-26
Recruiting
Eisai Inc.
Phase 2
64
Sapporo, Yokohama, Kumamuto-shi, Oskaka
2026-03-26
Recruiting
Bristol-Myers Squibb
Phase 3
850
Nagoya, Kobe, Nishinomiya, Sagamihara, Yokohama, Sendai, Hirakata, Sakai
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
Nagoya, Chiba, Kashiwa, Matsuyama, Yokohama, Kurashiki, Osaka, Suita
2026-03-13
Recruiting
Bristol-Myers Squibb
Phase 3
750
Toyohashi, Funabashi, Tōon, Sapporo, Nishinomiya, Kanazawa, Kamakura, Yokohama
2026-03-12
Recruiting
Pfizer
Phase 1/2
224
Yokohama, Suita, Shinjuku-ku, Fukuoka, Yamagata
2026-02-10
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Bunkyō City, Chiba, Kamakura-shi, Kamogawa, Kofu, Minato, Shibuya City, Yokohama
2026-02-04
Recruiting
Genmab
Phase 2
240
Sagamihara, Yokohama, Kyoto, Nagoya, Saitama, Sakai, Chūō, Tokyo
2026-01-30
Active, closed
Janssen Research & Development, LLC
Phase 2
189
Matsudo, Nishiku, Sakai, tabashi City, Tachikawa, Yokohama
2026-01-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Nagoya, Tōon, Kurume, Ōta, Sapporo, Akashi, Shiwa-gun, Yokohama
2026-01-19
Recruiting
Insmed Incorporated
Phase 3
344
Nagakute, Seto, Hirosaki, Narashino-shi, Narita-shi, Sapporo, Yokohama, Kyotoshi
2026-01-07
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Nagoya, Toyoake, Chiba, Kashiwa, Matsuyama, Sapporo, Kobe, Yokohama
2025-12-31
Active, closed
UCB Biopharma SRL
Phase 2
165
Habikino, Nagoya, Sakai, Sapporo, Tachikawa-shi, Yokohama
2025-12-29
Recruiting
Taiho Oncology, Inc.
Phase 3
360
Nagoya, Kurume-Shi, Hiroshima, Sapporo, Fukuoka, Akashi, Kobe, Yokohama
2025-12-22
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Bunkyō City, Hirakata, Kanazawa, Kobe, Sagamihara, Sunto Gun, Yokohama
2025-12-19
Active, closed
Amgen
Phase 3
250
Chikushino-shi, Fukuoka, Aki-gun, Kitahiroshima-shi, Yokohama, Kumamoto, Urasoe-shi, Osaka
2025-12-19
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 3
500
Yokohama, Chiba, Fukuoka, Kyoto, Tokyo
2025-12-15
Recruiting
Pfizer
Phase 3
800
Nagoya, Chiba, Kashiwa, Yokohama, Hidaka, Kitaadachi-gun, Nagaizumi-cho, Koto-ku
2025-12-11
Recruiting
Merck Sharp & Dohme LLC
Phase 2
150
Kashiwa, Yokohama, Chūō, Koto, Osaka
2025-12-04
Recruiting
Pfizer
Phase 3
450
Yokohama, Sakai, Setagaya-ku, Fukuoka
2025-12-02
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Kurume, Asahikawa, Sapporo, Yokohama, Sendai, Matsumoto, Ōmura, Kashihara
2025-11-30
Recruiting
Genmab
Phase 3
660
Chiba, Ōta, Shiwa-gun, Sagamihara-shi, Yokohama, Tsu, Sendai, Osaka
2025-11-28
Active, closed
Amgen
Phase 3
250
Chikushino-shi, Fukuoka, Aki-gun, Kitahiroshima-shi, Yokohama, Kumamoto, Urasoe-shi, Osaka
2025-11-25
Recruiting
Pfizer
Phase 2
165
Takasaki, Kawasaki-shi, Yokohama, Sakai, Chuo-ku
2025-11-20
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Nagoya, Kashiwa, Tōon, Kurume, Sapporo, Nishinomiya, Yokohama, Sendai
2025-11-05
Recruiting
Pfizer
Phase 2
200
Takasaki, Yokohama, Sakai, Tachikawa, Miyazaki
2025-10-30
Recruiting
GlaxoSmithKline
Phase 3
1,200
Gifu, Kanagawa, Kyoto, Musashino, Yokohama
2025-10-24
Active, closed
Bristol-Myers Squibb
Phase 2/3
470
Nagoya, Kashiwa, Sapporo, Yokohama, Chuo-ku, Koto, Osaka
2025-10-23
Recruiting
Bristol-Myers Squibb
Phase 1
32
Yokohama, Sunto-gun, Chuo-ku, Koto-ku
2025-10-15
Recruiting
Bristol-Myers Squibb
Phase 3
424
Toyoake, Ichikawa, Iizuka, Kitakyushu-shi, Sapporo, Yokohama, Karatsu, Bunkyo-ku
2025-10-08
Recruiting
Pfizer
Phase 2/3
982
Nagoya, Chiba, Kashiwa, Kita-gun, Kawasaki, Yokohama, Suita, Nagaizumi-cho
2025-10-03
Recruiting
Takeda
Phase 3
180
Nagoya, Hirosaki, Chūōku, Shirakawa, Sapporo, Zentsujichó, Kawasaki, Yokohama
2025-10-01
Recruiting
Pfizer
Phase 3
1,000
Chiba, Matsuyama, Sapporo, Kobe, Kanazawa, Yokohama, Yokosuka, Suita
2025-09-28
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
Nagoya, Chiba, Matsuyama, Otashi, Sapporo, Kanazawa, Isehara, Yokohama
2025-09-11
Recruiting
Janssen Research & Development, LLC
Phase 3
220
Bunkyō City, Funabashi Shi, Hakodate, Kawasaki, Minatoku, Sakura, Yokohama
2025-09-10
Recruiting
AbbVie
Observational
700
Maebashi, Asahikawa-shi, Sapporo, Kagoshima, Isehara, Yokohama, Kyoto, Kurashiki
2025-09-09
Recruiting
AbbVie
Phase 2
140
Nagoya, Kashiwa-shi, Fukuoka, Gifu, Yokohama, Sendai, Osaka, Sunto-gun
2025-09-02
Recruiting
Takeda
Phase 3
150
Chuo-ku, Narashino-shi, Ibaraki, Yokohama, Sendai, Hirakata-shi, Osaka, Suita-shi
2025-08-14
Active, closed
AstraZeneca
Phase 3
212
Kawasaki-shi, Kodaira-shi, Minatoku, Ōta-ku, Shinjuku-ku, Yokohama, Yufu-shi
2025-08-07
Recruiting
Sanofi
Phase 3
723
Nagoya, Sapporo, Kobe, Yokohama, Azumino, Shimajiri, Iruma, Koshigaya
2025-08-06
Recruiting
Pfizer
Phase 3
400
Chiba, Kashiwa, Matsuyama, Otashi, Isehara, Yokohama, Suita, Bunkyo-ku
2025-08-05
Recruiting
AbbVie
Phase 2/3
854
Yokohama, Niigata, Takatsuki, Sunto-gun, Bunkyo-ku, Chuo-Ku
2025-08-03
Recruiting
Sanofi
Phase 2
10
Sapporo, Kobe, Yokohama, Iruma, Chūō, Fukuoka, Kyoto, Nagasaki
2025-07-25
Recruiting
Pfizer
Phase 3
150
Yokohama, Sakai, Setagaya-ku, Fukuoka
2025-07-24
Recruiting
Pfizer
Phase 3
714
Tōon, Kurume, Otashi, Asahikawa, Kobe, Yokohama, Tsu, Sendai
2025-07-23
Recruiting
Bristol-Myers Squibb
Phase 3
450
Kōnan, Toyoake, Ichikawa, Iizuka, Kitakyushu, Obihiro, Sapporo, Yokohama
2025-07-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Nagoya, Kashiwa, Sapporo, Kita-gun, Yokohama, Sendai, Sakai, Hidaka
2025-07-16
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Sapporo, Yokohama, Bunkyo-ku, Shinjuku-ku, Chiba, Fukuoka, Okayama, Osaka
2025-07-14
Active, closed
Astellas Pharma Inc
Phase 4
17
Nagoya, Fukushima, Kita-gun, Yokohama, Kyoto, Nagasaki, Ginowan-shi, Hirakata-shi
2025-07-08
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Nagoya, Sapporo, Kobe, Kamakura, Yokohama, Kumamoto, Chuo Ku, Chiba
2025-07-01
Active, closed
Pfizer
Phase 1/2
74
Nagoya, Yokohama, Suita, Chuo-ku, Koto
2025-06-30
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
2,400
Nagoya, Matsuyama, Sapporo, Kahoku-gun, Yokohama, Tsu, Naha, Hirakata
2025-06-30
Active, closed
Bayer
Phase 3
36
Kurume, Himeji, Kobe, Tsukuba, Morioka, Sagamihara, Yokohama, Nankoku
2025-06-30
Recruiting
Pfizer
Phase 2
620
Kasugai, Matsudo, Sakura, Sapporo, Koga, Sagamihara, Yokohama, Tsu
2025-06-19
Recruiting
Immunovant Sciences GmbH
Phase 2
210
Nagoya, Kamogawa, Kitakyushu, Kurume, Minokamo, Maebashi, Yokohama, Nankoku
2025-06-19
Recruiting
Swedish Orphan Biovitrum
Phase 2
156
Fukushima, Nagasaki, Yokohama
2025-05-28
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Kashiwa, Sakura, Chikushino-shi, Maebashi, Shiwa-gun, Yokohama, Tsu, Sendai
2025-05-27
Recruiting
Biogen
Phase 3
180
Chia-shi, Urayasu-Shi, Sapporo, Kita-Gun Uchiko-Cho, Sagamihara-Shi Minami-Ku, Yokohama, Miyazaki, Niigata
2025-05-22
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Nagoya, Matsudo, Kawasaki, Yokohama, Habikino, Shinagawa Ku, Fukuoka, Kyoto
2025-05-16
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
Nagoya, Sapporo, Kanazawa, Sagamihara, Yokohama, Sendai, Kashihara, Kurashiki
2025-04-24
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
35
Nagoya, Kashiwa, Kurume, Nishinomiya, Sagamihara, Yokohama, Nankoku, Kyoto
2025-04-21
Active, closed
Philip Morris Products S.A.
Not applicable
290
Fukuoka, Gunma, Hyōgo, Tokyo, Yamagata, Yokohama, Yotsuya
2025-04-02
Recruiting
AstraZeneca
Phase 1/2
304
Kashiwa, Yokohama
2025-03-27
Active, closed
Amgen
Phase 3
3,853
Yokohama, Chiyoda-ku, Chuo-ku, Hachioji-shi, Minato-ku, Shinjuku-ku, Suginami-ku
2025-03-12
Recruiting
AbbVie
Phase 1/2
252
Nagoya, Hirosaki, Yokohama, Kyoto, Niigata, Takatsuki, Chuo-Ku, Koto-ku
2025-03-06
Recruiting
Novartis Pharmaceuticals
Phase 2/3
443
Kashiwa, Sapporo, Kobe, Yokohama, Chiba, Fukuoka, Fukushima, Ishikawa
2025-02-27
Recruiting
Takeda
Phase 3
171
Chuo-ku, Narashino-shi, Ibaraki, Yokohama, Sendai, Hirakata-shi, Osaka, Suita-shi
2025-02-27
Active, closed
Amgen
Phase 2
252
Kurume-shi, Sapporo, Yokohama, Niigata, Hirakata-shi, Osaka, Sunto-gun, Koto-ku
2025-02-26
Recruiting
Bristol-Myers Squibb
Phase 3
530
Matsuyama, Kurume, Sapporo, Kobe, Kanazawa, Yokohama, Sendai, Kashihara
2025-02-25
Recruiting
Amgen
Phase 3
844
Nagoya-shi, Nagoya, Sapporo, Kita Kyushu-shi, Tsukuba, Kahoku, Kanazawa, Yokohama
2025-02-25
Recruiting
Prevail Global Study
NCT06535854Coronary Artery Disease
Medtronic Vascular
Not applicable
1,205
Kitakyushu, Kamakura, Yokohama, Sendai, Itabashi-ku
2025-02-24
Active, closed
Sanofi
Phase 3
231
Ichikawa, Narita, Isehara, Odawara, Yokohama, Suwa, Kusatsu, Fukui
2025-02-12
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Nagoya, Fukuoka, Asahikawa, Ibaraki, Kagoshima, Sagamihara, Yokohama, Kanagawa
2025-01-08
Active, closed
Pfizer
Phase 3
1,035
Nagoya, Otashi, Sapporo, Yokohama, Sakyo-ku, Sendai, Suita, Bunkyo-ku
2025-01-06
Recruiting
Novartis Pharmaceuticals
Observational
30
Ōbu, Toyoake, Kurume, Sapporo, Tsukuba, Kawasaki, Yokohama, Tsu
2024-12-19
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Sapporo, Yokohama, Sendai, Suita, Izumo, Bunkyo-ku, Shinjuku-ku, Fukuoka
2024-12-17
Active, closed
Institut de Recherches Internationales Servier
Phase 1/2
55
Kashiwa, Chūōku, Kyoto, Yokohama
2024-12-16
Active, closed
Boston Scientific Corporation
Not applicable
186
Amagasaki, Yokohama, Kishiwada, Osaka, Kawagoe, Shizuoka, Minato, Wakayama
2024-12-13
Active, closed
Arcus Biosciences, Inc.
Phase 3
610
Kashiwa-shi, Kōtō City, Osaka, Tokyo, Toyama, Ube, Yokohama
2024-12-13
Active, closed
Amgen
Phase 3
707
Nagoya, Kashiwa-shi, Matsuyama, Maebashi, Sapporo, Kanazawa, Sagamihara-shi, Yokohama
2024-12-09
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Chiba, Kashiwa, Kōtoku, Kumamoto, Niigata, Okayama, Osaka, Yokohama
2024-11-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
67
Toyoake, Tōon, Kitakyushu, Takarazuka, Yokohama, Nankoku, Natori-shi, Sakai
2024-11-21
Active, closed
A Study of Mosliciguat in PH-ILD
NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
DrugMosliciguat
Pulmovant, Inc.
Phase 2
135
Narashino, Sapporo, Kobe, Yokohama, Okayama, Suita, Chiyoda City
2024-10-29
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
196
Fuchū, Kanazawa, Kobe, Kumamoto, Matsumoto, Saga, Yokohama
2024-10-29
Recruiting
Pfizer
Phase 3
900
Chiba, Kashiwa, Matsuyama, Sapporo, Kobe, Kanazawa, Yokohama, Yokosuka
2024-10-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Kashiwa, Kitakyushu, Kawasaki, Yokohama, Hirakata, Sakai, Sunto-gun, Shimotsuga-gun
2024-10-21
Active, closed
Pfizer
Phase 3
600
Chiba, Kashiwa, Matsuyama, Sapporo, Kobe, Kanazawa, Yokohama, Yokosuka
2024-10-21
Active, closed
Revolution Medicines, Inc.
Phase 3
500
Chiba, Nagoya, Osaka, Tokyo, Yokohama
2024-10-16
Active, closed
Novartis Pharmaceuticals
Phase 2
201
Nagoya, Toyoake, Yokohama, Iruma-gun, Bunkyo-ku, Shinjuku Ku, Toyama, Hiroshima
2024-10-09
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Nakamura-ku,Nagoya, Kashiwa, Kitakyushu, Kurume, Fukuyama-shi, Sapporo, Sagamihara, Yokohama
2024-10-07
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
2,150
Ōgaki, Maebashi, Fukui-shi, Yokohama, Kyoto, Suita-shi, Bunkyō-Ku, Minato-Ku
2024-10-04
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Chiba, Sapporo, Kobe, Yokohama, Sendai, Suita, Izumo, Bunkyo Ku
2024-09-04
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
Kashiwa, Yokohama
2024-08-22
Recruiting
Sanofi
Phase 3
160
Yokohama, Higashi-Matsuyama, Kawagoe, Yaizu, Kodaira, Ōta-ku, Amagasaki, Chiba
2024-08-21
Active, closed
Vor Biopharma
Phase 3
191
Nagoya, Sapporo, Kobe, Kawasaki, Yokohama, Sendai, Kashiwazaki-Shi, Ginowan-Shi
2024-07-17
Active, closed
AstraZeneca
Phase 3
339
Chūōku, Fukuoka, Kanazawa, Kita-gun, Nagoya, tabashi City, Wakayama, Yokohama
2024-06-29
Active, closed
Novartis Pharmaceuticals
Phase 3
162
Fukuoka, Asahikawa, Kita-gun, Sagamihara, Yokohama, Nagano, Kawachi-Nagano, Osaka
2024-06-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Nagoya, Kashiwa, Ōta, Sapporo, Isehara, Kawasaki, Sagamihara, Yokohama
2024-06-24
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
220
Kashiwa, Yokohama
2024-06-20
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
Toyoake, Tōon, Fukuoka, Ōta, Kanazawa, Kawasaki, Yokohama, Natori-shi
2024-06-11
Active, closed
Amgen
Phase 3
563
Nagoya, Kashiwa-shi, Matsuyama, Fukuoka, Kurume-shi, Sapporo, Akashi-shi, Yokohama
2024-06-05
Active, closed
Amgen
Phase 1
120
Nagoya, Kashiwa-shi, Yokohama, Chuo-ku
2024-05-29
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Nagoya, Sapporo, Yokohama, Sendai, Bunkyo-ku, Chuo Ku, Fuchū, Itabashi-ku
2024-05-21
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
220
Sakura, Yokohama, Mitato, Fukuoka
2024-05-20
Active, closed
Sanofi
Phase 3
1,541
Chitose, Obihiro, Sapporo, Kobe, Sagamihara, Yokohama, Miyagi-gun, Sendai
2024-05-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Nagoya, Kashiwa, Sapporo, Isehara, Kawasaki, Sagamihara, Yokohama, Tsu
2024-04-14
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Funabashi Shi, Hakodate, Hyōgo, Niigata, Okayama, Sakura, Tokyo, Yokohama
2024-04-09
Active, closed
Amgen
Phase 3
434
Nagoya, Sapporo, Kita Kyushu-shi, Nishinomiya-Shi, Tsukuba, Kahoku, Kanazawa, Yokohama
2024-04-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Kashiwa, Matsuyama, Kitakyushu, Kobe, Kawasaki, Yokohama, Hirakata, Sakai
2024-04-03
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
89bio, Inc.
Phase 3
1,350
Maebashi, Sapporo, Hizume, Kawasaki, Yokohama, Ehime, Fukuoka, Gifu
2024-03-13
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Kashiwa, Sapporo, Kobe, Yokohama, Chuo Ku, Fukuoka, Fukushima, Ishikawa
2024-03-12
Recruiting
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06217822Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression
Bayer
Phase 1
198
Yokohama, Koto-ku
2024-03-07
Active, closed
Sanofi
Phase 3
464
Yokohama, Habikino, Sakai, Mibu, Minato, Tachikawa, Hiroshima, Sapporo
2024-02-29
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Nagoya, Kashiwa-shi, Matsuyama, Kurume, Ota-Shi, Kobe, Kanazawa, Yokohama
2024-02-21
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Nagoya, Kashiwa-shi, Matsuyama, Kurume-shi, Sapporo, Yokohama, Sendai, Niigata
2024-02-20
Active, closed
Pfizer
Phase 1/2
71
Kashiwa, Yokohama, Chuo-ku, Tokyo
2024-02-19
Recruiting
A Study of KK2269 in Adult Participants With Solid Tumors
NCT06266299Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugDocetaxel
Kyowa Kirin Co., Ltd.
Phase 1
101
Nagoya, Toyoake, Kashiwa, Matsuyama, Kurume, Kobe, Yokohama, Hirakata
2024-01-18
Active, closed
Bristol-Myers Squibb
Phase 3
190
Nagoya, Kashiwa, Matsuyama, Sapporo, Yokohama, Sendai, Bunkyo Ku, Yonago
2023-12-21
Active, closed
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
NCT06046222Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
NS Pharma, Inc.
Phase 2
45
Chuo-ku, Chiba-shi, Kitakyushu, Sapporo, Sagamihara, Yokohama, Sendai, Habikino, Kawagoe
2023-12-20
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Nagoya, Kashiwa-shi, Kurume, Kanazawa, Yokohama, Kyoto, Sendai, Ōsaka-sayama
2023-12-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Sakura, Eiheiji-cho,Yoshida-gun, Kitakyushu, Sapporo, Kobe, Mukai-awagasaki, Kita, Yokohama
2023-12-18
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
285
Nagoya, Hirosaki-Shi, Fukuoka, Sagamihara, Yokohama, Kumamoto, Sendai, Okayama
2023-12-18
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
87
Nagoya, Kashiwa-shi, Kanazawa, Yokohama, Osaka, Hamamatsu, Bunkyo-ku, Koto-Ku
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Nagoya, Hirosaki, Kashiwa, Akashi, Kawasaki, Yokohama, Sendai, Hirakata
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Nagoya, Toyoake, Kashiwa, Matsuyama, Otashi, Takarazuka, Kanazawa, Yokohama
2023-11-12
Recruiting
Kyowa Kirin Co., Ltd.
Phase 1
189
Nagoya, Kashiwa, Matsuyama, Hiroshima, Kobe, Yokohama, Kumamoto, Sendai
2023-11-01
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Nagoya, Kitakyushu, Sapporo, Yokohama, Kuwana, Sasebo, Kurashiki, Bunkyo Ku
2023-10-27
Active, closed
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
NCT06049212Non-small Cell Lung Cancer, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
DrugsSacituzumab tirumotecan·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1
30
Nagoya, Kashiwa, Matsuyama, Yokohama, Hirakata, Nagaizumi-cho,Sunto-gun, Chuo-ku
2023-10-26
Active, closed
Merck Sharp & Dohme LLC
Phase 2
19
Nagoya, Sapporo, Yokohama, Sendai, Matsumoto, Niigata, Hidaka, Izumo
2023-10-20
Recruiting
CellSeed Inc.
Phase 3
96
Ebina, Isehara, Yokohama, Bunkyō-Ku
2023-10-20
Active, closed
Servier
Phase 2
12
Kashiwa, Kumamoto, Matsuyama, Osaka, Sapporo, Tokyo, Yokohama
2023-10-10
Recruiting
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
NCT06038578Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsTRK-950·Ramucirumab·Paclitaxel
Toray Industries, Inc
Phase 2
146
Yokohama, Shinden, Nagaizumi-cho, Chūōku, Kashiwa, Kōtoku
2023-10-04
By invitation
Biogen
Phase 3
306
Nagoya, Yoshida-gun, Kitakyushu-shi, Kakogawa-shi, Kanazawa, Kawasaki-shi, Yokohama, Kumamoto
2023-10-03
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
412
Fukuoka, Ota-Shi, Kobe, Tsukuba, Kita-gun, Yokohama, Tokushima, Wakayama
2023-09-22
Active, closed
AbbVie
Phase 2
130
Chiba, Kashiwa-shi, Kanazawa, Yokohama, Osakasayama-shi
2023-09-21
Recruiting
Protara Therapeutics
Phase 2
131
Komaki-shi, Nagoya, Funabashi-shi, Sakura-shi, Fukuoka, Amagasaki-shi, Hitachi-shi, Yokohama
2023-09-15
Recruiting
Pfizer
Phase 2
340
Yokohama, Osaka, Chuo-ku, Setagaya-ku
2023-08-22
Recruiting
Haihe Biopharma Co., Ltd.
Phase 1/2
141
Sapporo, Kobe, Yokohama, Sendai, Matsumoto, Mitaka, Gifu
2023-08-22
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Kasugai-Shi, Toyoake-shi, Urayasu-Shi, Sapporo, Kitakyushu, Yokohama, Kashihara, Nara
2023-07-06
Active, closed
AstraZeneca
Phase 3
111
Kanazawa, Kashiwa, Matsuyama, Musashino-shi, Osakasayama-shi, Yokohama
2023-06-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
39
Toyoake, Kurume, Otashi, Sapporo, Yokohama, Natori-shi, Sendai, Kurashiki
2023-06-13
Active, closed
Eli Lilly and Company
Phase 3
3,127
Wakasugi, Aki-gun, Tsuchiura, Takamatsu, Zentsujichó, Yokohama, Suita-shi, Sōka
2023-06-05
Active, closed
Amgen
Phase 3
509
Nagoya, Kashiwa-shi, Matsuyama, Kurume-shi, Sapporo, Akashi-shi, Yokohama, Sendai
2023-05-31
Recruiting
Chugai Pharmaceutical
Phase 1
209
Nagoya, Kashiwa-shi, Yokohama, Hirakata-shi, Osaka, Sakai-shi, Nagaizumi-chō, Chuo-ku
2023-05-24
Active, closed
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
NCT05831176Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
DrugDupilumab
Regeneron Pharmaceuticals
Phase 2
22
Iizuka, Ōgaki, Kure, Himeji, Kobe, Yokohama, Kurashiki, Minato-ku
2023-05-03
Active, closed
AstraZeneca
Phase 2
294
Chūōku, Kashiwa, Yokohama
2023-04-24
Active, closed
Bayer
Phase 3
985
Sapporo, Kanazawa, Yokohama, Suita, Bunkyo-ku, Kyoto
2023-04-03
Active, closed
Sanofi
Phase 2
999
Obihiro, Yokohama, Sakai, Mibu, Tachikawa
2023-04-03
Active, closed
Multi-omics Study in Citrin Deficiency
NCT06895746Citrin Deficiency
Johannes Haeberle
Observational
100
Kurume-shi, Saitama, Yokohama, Tokyo, Sendai, Matsumoto, Hokkaido, Osaka
2023-04-01
Active, closed
Pfizer
Phase 3
624
Nagoya, Chiba, Kashiwa, Sapporo, Yokohama, Suita, Ina-machi, Bunkyo-ku
2023-03-03
Active, closed
Novartis Pharmaceuticals
Phase 3
436
Nagoya, Sapporo, Yokohama, Sendai, Bunkyo Ku, Bunkyo-ku, Chuo Ku, Fuchū
2023-03-02
Recruiting
Lantern Pharma Inc.
Phase 2
90
Sapporo, Yokohama, Sendai, Okayama, Chuo-ku
2023-03-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
377
Toyoake, Kurume, Ōta, Sapporo, Yokohama, Natori-shi, Sendai, Kurashiki
2023-02-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Nagoya, Matsuyama, Kurume, Takarazuka, Kanazawa, Yokohama, Natori-shi, Sendai
2023-02-06
Active, closed
Hoffmann-La Roche
Phase 3
1,290
Sapporo, Miura-shi, Sagamihara-shi, Yokohama, Matsusaka-Shi, Ginowan-shi, Fujieda-Shi, Ube-shi
2022-12-29
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Nagoya, Urayasu, Obihiro, Yokohama, Kamimashi-gun, Izumiōtsu, Neyagawa, Sakai
2022-12-09
Active, closed
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
DrugsVabysmo·Faricimab
Hoffmann-La Roche
Observational
6,000
Nagakute-shi, Nagoya, Sakura-shi, Sapporo, Kobe, Yokohama, Shimotsuke-shi, Chiyoda-ku
2022-11-21
Active, closed
Biogen
Phase 2
416
Toon-shi, Himeji-shi, Kawasaki-shi, Yokohama, Osaka, Suita-shi, Itabashi-ku
2022-08-24
Active, closed
A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
NCT05814159Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset
DrugAnakinra
Swedish Orphan Biovitrum
Phase 3
15
Fukushima, Kobe, Yokohama, Matsumoto, Bunkyō-Ku, Shinjuku-Ku, Gifu
2022-08-24
Active, closed
Sanofi
Phase 2/3
1,856
Chitose, Obihiro, Sapporo, Sagamihara, Yokohama, Habikino, Sakai, Iruma
2022-08-22
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
220
Chūōku, Kashiwa-shi, Kitaadachi-gun, Kōtoku, Nagoya, Osakasayama-shi, Sunto-gun, Yokohama
2022-08-04
Active, closed
Novartis Pharmaceuticals
Phase 3
506
Nagoya, Kitakyushu, Sapporo, Yokohama, Kuwana, Sasebo, Kurashiki, Bunkyo Ku
2022-08-04
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 2/3
12
Yokohama
2022-06-23
Recruiting
Astellas Pharma Inc
Phase 1
681
Nagoya, Kashiwa, Matsuyama, Kurume, Sapporo, Yokohama, Sendai, Niigata
2022-06-08
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
398
Nagoya, Kashiwa, Yokohama, Sakai, Suita, Chuo-ku, Koto-ku
2022-06-07
Recruiting
Dimerix Bioscience Pty Ltd
Phase 3
286
Kasugai, Toyoake, Chiba, Ichihara, Higashi, Yokohama, Asahikawa, Sapporo
2022-05-30
Recruiting
Bristol-Myers Squibb
Phase 2/3
120
Ōbu, Kurume-shi, Komatsu, Yokohama, Takatsuki, Bunkyo-Ku, Setagaya-ku, Shinjuku-ku
2022-05-30
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Nagoya, Kashiwa, Matsuyama, Kurume, Sapporo, Kanazawa, Yokohama, Sendai
2022-03-24
Active, closed
COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events
NCT05333068Multivessel Coronary Artery Disease, Ischemia, Vulnerable Plaque, Coronary Artery Disease
Diagram B.V.
Not applicable
1,223
Bunkyō City, Yokohama
2022-03-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Toyoake, Kashiwa, Sakura, Tōon, Sapporo, Yokohama, Kashihara, Sakai
2022-03-15
Active, closed
BeOne Medicines
Phase 3
799
Matsuyama, Hiroshima, Sapporo, Kagoshima, Yokohama, KyotoShi, Okayama, Hirakata
2022-03-10
Active, closed
Daiichi Sankyo
Phase 2
187
Chūōku, Kashiwa, Kōtoku, Nagaizumi-chō, Osaka, Ōsaka-sayama, Yokohama
2022-03-09
Active, closed
Daiichi Sankyo
Phase 3
740
Aomori, Kashiwa-shi, Matsuyama, Fukuoka, Kurume-shi, Kanazawa, Yokohama, Kumamoto
2022-03-04
Recruiting
Sanofi
Phase 3
284
Matsudo, Urayasu, Sapporo, Yokohama, Habikino, Sakai, Izumo, Tachikawa
2022-02-15
Active, closed
Biogen
Phase 3
45
Yokohama, Toyonaka-shi
2022-01-21
Recruiting
Novartis Pharmaceuticals
Phase 1/2
34
Yokohama, Shinjuku-ku, Osaka
2021-12-27
Active, closed
Eli Lilly and Company
Phase 3
152
Nagoya, Kashiwa, Himeji, Yokohama, Niigata, Nakatogari, Koto, Yonago
2021-12-20
Recruiting
Merck Sharp & Dohme LLC
Phase 1
830
Kashiwa, Yokohama, Nakatogari, Chuo-ku, Koto
2021-12-17
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Toyota, Chikushino-shi, Kanazawa, Komatsu, Fujisawa, Odawara, Yokohama, Nagaoka
2021-11-23
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 3
626
Kashiwa-shi, Yokohama, Osaki-shi, Suita-shi, Hidaka-shi, Ina-machi, Kitaadati-gun, Nagaizumi-Cho, Sunto-Gun, Bunkyo-ku
2021-11-05
Recruiting
Bayer
Phase 1/2
430
Nagoya, Kashiwa, Matsuyama, Sapporo, Yokohama, Sakai, Sunto, Chuo-ku
2021-10-25
Active, closed
AbbVie
Phase 1
520
Nagoya, Kashiwa-shi, Yokohama, Kyoto, Niigata, Chuo-ku, Koto-ku, Wakayama
2021-10-13
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
65
Toyoake, Chiba, Kashiwa, Sapporo, Kobe, Kawasaki, Yokohama, Kurashiki
2021-09-23
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Kasugai, Toyoake, Toyota, Sapporo, Kawasaki, Yokohama, Kyoto, Sendai
2021-09-20
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
689
Nagoya, Chiba, Kashiwa, Kotoku, Yokohama
2021-09-13
Active, closed
Pfizer
Phase 3
38,861
Fukuoka, Itoshima, Amagasaki, Yokohama, Osaka, Kawaguchi, Chuo-ku, Hachioji-shi
2021-08-31
Recruiting
Merck Sharp & Dohme LLC
Phase 2
355
Sapporo, Yokohama, Nankoku, Chuo-ku, Kyoto, Tokyo
2021-08-12
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
32
Kashiwa-shi, Yokohama, Hamamatsu, Bunkyō-Ku, Koto-ku, Mitaka-shi, Shinjuku-Ku, Chūōku
2021-07-30
Active, closed
Janssen Research & Development, LLC
Phase 1
216
Kashiwa, Yokohama
2021-07-13
Active, closed
AstraZeneca
Phase 3
506
Isehara, Kawasaki-shi, Sapporo, Shinagawa-ku, Yokohama
2021-06-22
Recruiting
NCCH2006/MK010 Trial (FORTUNE Trial)
NCT04962867Advanced or Recurrent Solid Tumors, FGFR Gene Alterations
National Cancer Center, Japan
Phase 2
75
Chuo-ku, Tokyo, Yokohama, Aoba-ku, Sendai, Miyagi, Higashi-Ku, Fukuoka, Kita-Ku, Sapporo, Hokkaido, Okayama, Sakyo-ku, Kyoto
2021-06-15
Active, closed
Daiichi Sankyo
Phase 1
246
Matsuyama, Fukuoka, Sapporo, Yokohama, Okayama, Chuo Ku, Iwakuni-shi, Ōsaka-sayama
2021-06-11
Active, closed
Novartis Pharmaceuticals
Phase 3
1,140
Nagoya, Sapporo, Kobe, Yokohama, Kumamoto, Suita, Kitaadachi-gun, Bunkyo Ku
2021-06-09
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
Bunkyō, Bunkyō City, Kashiwa, Kobe, Tokyo, Yokohama
2021-05-26
Active, closed
Novartis Pharmaceuticals
Phase 2
36
Narita, Kurume, Ohtake, Nishinomiya, Kanazawa, Isehara, Yokohama, Sendai
2021-05-25
Active, closed
Savara Inc.
Phase 3
164
Chiba, Sapporo, Yokohama, Kumamoto, Sendai, Sakai, Saitama, Mitaka
2021-05-19
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Nagoya, Hirosaki, Tsukuba, Kanazawa, Sagamihara, Yokohama, Sendai, Hamamatsu
2021-04-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,688
Toyoake, Kashiwa, Tōon, Sapporo, Yokohama, Kashihara, Sayama, Suita
2021-04-14
Active, closed
Pfizer
Phase 2
66
Nagoya, Kashiwa, Matsuyama, Sapporo, Akashi, Nishinomiya, Tsukuba, Yokohama
2021-04-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
747
Toyoake, Kashiwa, Sakura, Sapporo, Kobe, Yokohama, Kashihara, Sakai
2021-02-25
Active, closed
AstraZeneca
Phase 1
155
Kōtoku, Sunto-gun, Yokohama
2021-02-02
Recruiting
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT04031677Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
250
Higashiku, Yokohama, Sendai, Chikusa-ku, Shōwaku, Niigata, Kita-ku, Chuo-ku
2021-01-20
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
40
Kashiwa-shi, Kobe, Yokohama, Ina, Osaka, Takatsuki-shi, Hidaka-shi, Koto-Ku
2021-01-13
Active, closed
Novartis Pharmaceuticals
Phase 2
24
Nagoya, Kashiwa, Isehara, Yokohama, Kumamoto, Sendai, Osaka, Suita
2021-01-08
Active, closed
Amgen
Phase 1/2
181
Akita, Kashiwa-shi, Fukushima, Yokohama, Yokohami-shi
2021-01-04
Active, closed
Pfizer
Phase 3
841
Chiba, Kashiwa, Sapporo, Kanazawa, Kawasaki, Yokohama, Nagoya, Osaka
2020-12-21
Active, closed
The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries
NCT04192747Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Elixir Medical Corporation
Not applicable
445
Kitakyushu, Kurume, Sapporo, Tsuchiura, Kagoshima, Kamakura, Kawasaki-shi, Yokohama
2020-12-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
672
Nagoya, Kobe, Takarazuka, Yokohama, Hirakata, Takatsuki, Nakatogari, Fukuoka
2020-12-08
Recruiting
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT04606446Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
DrugsPrifetrastat·Atirmociclib·Palbociclib·Letrozole
Pfizer
Phase 2
320
Nagoya, Kashiwa, Yokohama, Chuo-ku
2020-11-16
Active, closed
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT04452591Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
DrugCretostimogene Grenadenorepvec
CG Oncology, Inc.
Phase 3
190
Kashiwa-shi, Tōon, Sapporo, Kandori, Marugame, Kawasaki, Yokohama, Kyoto
2020-10-27
Active, closed
Eli Lilly and Company
Phase 1
200
Kashiwa, Yokohama, Suita-shi, Nakatogari, Chuo-ku
2020-10-01
Active, closed
ADC Therapeutics S.A.
Phase 3
440
Nagoya, Toyohashi, Kashiwa, Matsuyama, Ōta, Sapporo, Kobe, Yokohama
2020-09-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Kurume, Kobe, Yokohama, Hirakata, Takatsuki, Fukuoka, Niigata, Osaka
2020-07-06
Recruiting
Chiome Bioscience Inc.
Phase 1
66
Kashiwa, Yokohama, Niigata, Chūō
2020-06-01
Recruiting
Amgen
Phase 1
479
Kashiwa-shi, Yokohama, Koto-ku
2020-03-04
Active, closed
Merck Sharp & Dohme LLC
Phase 3
755
Toyoake, Kashiwa, Tōon, Sapporo, Yokohama, Kashihara, Sayama, Suita
2020-02-27
Active, closed
Eli Lilly and Company
Phase 3
261
Kashiwa, Sapporo, Kanazawa, Yokohama, Osaka Sayama-shi, Nakatogari, Chuo-ku, Koto
2020-02-17
Active, closed
Eli Lilly and Company
Phase 3
58
Bunkyō, Chiba, Kagoshima, Sendai, Takatsuki, Yokohama
2020-02-12
Active, closed
Loxo Oncology, Inc.
Phase 3
291
Nagoya, Kashiwa, Sapporo, Kobe, Yokohama, Suita, Koto, Fukuoka
2020-02-11
Active, closed
AbbVie
Phase 3
56
Chiba, Toon-shi, Maebashi, Sapporo, Tsukuba, Kita-gun, Kawasaki-shi, Yokohama
2020-02-04
Active, closed
Takeda
Phase 3
354
Toyoake-Shi, Kashiwa-Shi, Matsuyama, Sapporo, Kurume-Shi, Yokohama, Kumamoto, Natori-shi
2020-01-10
Active, closed
Pfizer
Phase 3
1,068
Matsuyama, Tōon, Fukuoka, Ōta, Sapporo, Yokohama, Osaka, Sakai
2019-12-30
Active, closed
Bristol-Myers Squibb
Phase 3
461
Nagoya, Kashiwa-shi, Kitakyushu-shi, Hiroshima, Kobe, Kanazawa, Yokohama, Sendai
2019-11-05
Active, closed
Eisai Co., Ltd.
Phase 1/2
125
Nagoya, Kashiwa, Matsuya, Kurume, Akashi, Yokohama, Sendai, Chuo Ku
2019-09-05
Active, closed
BeOne Medicines
Phase 3
510
Nagoya, Toyohashi, Chiba, Kurume, Hiroshima, Yokohama, Kumamoto, Kyoto
2019-08-20
Active, closed
Sanofi
Observational
1,860
Sagamihara, Yokohama, Tsu, Habikino, Fuchū, Fukuoka, Fukuyama-shi, Hiroshima
2019-08-15
Active, closed
National Cancer Center Hospital East
Phase 2
51
Nagoya, Kashiwa, Hokkaido, Akashi, Kobe, Yokohama, Sendai, Osaka
2019-07-02
Active, closed
AstraZeneca
Phase 3
810
Chūōku, Kashiwa, Kitaadachi-gun, Mitaka-shi, Osaka, Suita-shi, Wakayama, Yokohama
2019-04-16
Active, closed
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
DrugsZolbetuximab·Nab-paclitaxel·Gemcitabine
Astellas Pharma Global Development, Inc.
Phase 2
393
Nagoya, Kashiwa, Sapporo, Yokohama, Kashihara, Bunkyo-ku, Chuo-ku, Koto-ku
2019-03-15
Active, closed
Takeda
Phase 1
53
Nagoya, Toyoake, Kashiwa, Kurume, Sapporo, Akashi, Kanazawa, Yokohama
2019-02-04
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
Fukuoka, Akashi, Kawasaki, Yokohama, Suita, Utsunomiya, Chiba, Kashiwa
2018-11-28
Active, closed
Eli Lilly and Company
Phase 2/3
393
Nagoya, Hirosaki, Sakura, Sapporo, Kobe, Kanazawa, Yokohama, Ina-machi
2018-11-26
Recruiting
Novartis Pharmaceuticals
Observational
700
Nagakute-shi, Toyoake-shi, Chiba, Kurume-shi, Gifu, Sapporo, Kita-gun, Yokohama
2018-09-25
Active, closed
AbbVie
Phase 3
1,533
Nagoya, Fukuoka, Hiroshima, Sapporo, Amagasaki-shi, Sagamihara-shi, Yokohama, Kyoto
2018-08-09
Active, closed
pharmaand GmbH
Phase 3
1,097
Tsukuba, Kashiwa, Kurume, Yokohama, Maebashi, Ota-shi, Naka, Akashi
2018-05-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Nagoya, Kashiwa, Kitakyushu, Akashi, Kawasaki, Yokohama, Yufu, Fukushima
2018-04-24
Active, closed
Pfizer
Phase 3
1,054
Nagoya, Hirosaki, Kashiwa, Matsuyama, Kure, Sapporo, Kanazawa, Yokohama
2017-12-18
Active, closed
Takara Bio Inc.
Phase 1
36
Nagoya, Chiba, Kashiwa, Yokohama, Osaka, Chūōku, Koto-Ku
2017-09-25
Active, closed
Eisai Co., Ltd.
Phase 1
140
Kashiwa, Sapporo, Nishinomiya, Yokohama, Hidaka, Bunkyo-ku, Chuo-ku, Koto-ku
2017-08-18
Active, closed
Regeneron Pharmaceuticals
Phase 1
146
Nagoya, Kurume, Ōta, Kobe, Kanazawa, Sagamihara, Yokohama, Sasebo
2017-06-21
Recruiting
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor, Malignant Germ Cell Tumor
DrugsBleomycin·Cis-platinum·CDDP·Paraplatin
Children's Oncology Group
Phase 3
1,780
Sendai, Chiba-sgi, Niigata, Higashiku, Sapporo, Kobe, Tsukuba, Yokohama
2017-05-25
Active, closed
Pfizer
Phase 3
296
Nagoya, Matsuyama, Kurume, Sapporo, Kanazawa, Yokohama, Sendai, Osaka
2017-04-27
Recruiting
Turning Point Therapeutics, Inc.
Phase 1/2
500
Tōon, Sapporo, Yokohama, Osaka, Chuo-ku, Yonago, Kashiwa, Nagoya
2017-03-07
Active, closed
Astellas Pharma Global Development, Inc.
Phase 2
900
Sakura-shi, Higashiku, Maebashi, Kida-gun, Yokohama, Sayama, Bunkyo-ku, Koutou-ku
2016-12-22
Recruiting
UMC Utrecht
Phase 3
20,000
Kawasaki, Yokohama, Minami, Osaka, Tokyo, Wakayama
2016-04-11
Active, closed
Bayer
Phase 1/2
154
Yokohama, Chuo-ku, Fukuoka
2015-12-16
Active, closed
Medtronic
Observational
3,100
Mitaka-shi, Shinagawa, Suita, Yokohama
2015-07
Active, closed
Eli Lilly and Company
Phase 3
493
Nagoya, Chiba, Matsuyama, Sapporo, Nishinomiya, Yokohama, Niigata, Ōsaka-sayama
2014-11-06
Rows per page Showing 1–275 of 275
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/yokohama

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 275 of those studies with a site in Yokohama.

How many clinical trials are recruiting in Yokohama?

127 of the 275 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 6 have not yet opened recruitment, 141 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Yokohama), 275 studies
PhaseStudiesRecruitingShare
Phase 31466253.1%
Phase 2542819.6%
Phase 127109.8%
Phase 1/219136.9%
Phase 2/31284.4%
Observational1053.6%
Not applicable511.8%
Phase 4200.7%

Most active sponsors

Lead sponsors with the most studies (Yokohama)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC3214
Novartis Pharmaceuticals2714
Pfizer2715
Bristol-Myers Squibb1713
Amgen143
AstraZeneca125
Sanofi104
AbbVie95
Eli Lilly and Company81
Janssen Research & Development, LLC74
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.